R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

Xenotransplantation at the brink of breakthrough: A new era ...

In a landmark procedure performed at Massachusetts General Hospital (MGH) on 25th January 2025, a 66-year-old man with end-stage renal disease (ESRD) received a genetically modif

R&D

Mind the gap: The need for gender-specific outcome measureme...

It is well documented that women face delayed diagnoses, mischaracterised symptoms, and experience more years of ill-health compared to men.

R&D

Can sound waves ease depression symptoms?

Depression affects more than 280 million people worldwide.

R&D

Why I'm focused on the trillion-dollar AMR crisis everyone's...

AMR demands sustained commitment beyond conventional market incentives.

R&D

Interview at HLTH 2025 with Scott Honken

WeightWatchers’ Scott Honken on rethinking success in the ag...

At HLTH Europe, Deep Dive editor Eloise McLennan sat down with Scott Honken, chief commercial officer at WeightWatchers.

R&D

a hand sprouts money plant a man plucks a coin from

Grants for funding pharmaceutical research: Growing without ...

Whilst equity investment is likely to be central to the funding strategy of many early-stage biotechs, grant funding can be a very useful alternative.